← Browse by Condition
Medical Condition
oligoprogressive metastatic disease
Total Trials
2
Recruiting Now
2
Trial Phases
Various
ClinicalMetric tracks all active clinical trials for oligoprogressive metastatic disease sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Top Sponsors
1 trial
1 trial
Recruiting Clinical Trials
NCT06918951
Recruiting
Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers
Enrollment
194 pts
Location
Canada
Sponsor
British Columbia Cancer Agency
NCT06925984
Recruiting
Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)
Enrollment
48 pts
Location
Belgium
Sponsor
Jules Bordet Institute
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology